Revolution Medicines’ Pancreatic Cancer Drug Hits Phase 3 Trial Goal

Revolution Medicines announced on April 13, 2026, that its pancreatic cancer drug daraxonrasib met all primary and key secondary endpoints in the pivotal Phase 3 RASolute 302 clinical trial. The trial focused on patients with previously treated metastatic pancreatic ductal adenocarcinoma.

The company reported that daraxonrasib, an oral once-daily RAS inhibitor, demonstrated a median overall survival of 13.2 months. This result compared to a median overall survival of 6.7 months for patients who received standard cytotoxic chemotherapy.

Clinical Trial Results

The RASolute 302 trial provided a hazard ratio of 0.40 for overall survival, with a p-value of less than 0.0001. Reporting from CNBC indicated that the drug succeeded in slashing the risk of death by 60% compared to the chemotherapy arm.

The study population consisted of patients with RAS-driven pancreatic cancers, with more than 90% of the participants possessing RAS-mutated tumors.

Regulatory Path and Next Steps

Revolution Medicines intends to proceed with global regulatory submissions for the drug. In the United States, the company plans to submit a New Drug Application (NDA) to the FDA under a Commissioner’s National Priority Voucher.

The company stated it will present the full data from the RASolute 302 trial at the ASCO 2026 Annual Meeting.

Broader Development Program

The success of the RASolute 302 trial follows other efforts by Revolution Medicines to target RAS-mutated cancers. On September 10, 2025, the company initiated RASolute 303, which is a global Phase 3 registrational trial testing daraxonrasib in the first-line treatment of metastatic pancreatic ductal adenocarcinoma.

The company has spent more than 15 years investing in RAS(ON) research and currently has four clinical-stage RAS(ON) drugs in its investigational inhibitor programs.

Following the announcement of the trial results on April 13, 2026, Revolution Medicines (NASDAQ:RVMD) shares were priced at $96.43.

• Median overall survival (daraxonrasib): 13.2 months
• Median overall survival (chemotherapy): 6.7 months
• Hazard ratio: 0.40
• P-value: p < 0.0001
• Patient mutation rate: Over 90% RAS-mutated tumors